Last updated: March 2, 2026
What is NDC 70515-0737?
National Drug Code (NDC) 70515-0737 identifies a specific pharmaceutical product. It corresponds to Vaxneuvance (Pneumococcal 15-valent conjugate vaccine) manufactured by Merck & Co. It is used to prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria in adults and children.
Market Context
Indications and Use
Vaxneuvance offers protection against 15 types of pneumococcal bacteria, including the 13 serotypes covered by Prevnar 13 plus 2 additional serotypes. It gained FDA approval in July 2021 for adults aged 18 and older, with expansion to pediatric use under ongoing trials.
Market Size
The global pneumococcal vaccine market was valued at approximately $4.2 billion in 2022. It is projected to grow at a CAGR of 8.9% through 2030, driven by:
- Rising pneumococcal disease prevalence
- Increased vaccination awareness
- Expanded indications for vaccines
In the U.S., the adult pneumococcal vaccination market segment represents around $350 million annually, with potential growth as new formulations and indications expand usage.
Competitive Landscape
Key competitors include:
- Prevnar 13 (Pfizer)
- Pneumovax 23 (Merck)
- Other conjugate and polysaccharide vaccines in development or limited markets
Vaxneuvance launched into a competitive space dominated by Prevnar 13, with a notable market share due to broader serotype coverage.
Regulatory and Reimbursement Factors
- FDA approval date: July 2021.
- ACIP (CDC Advisory Committee on Immunization Practices) recommendations: Support use in adults aged 19 and older, emphasizing high-risk populations.
- Coverage: Medicare Part D includes Vaxneuvance, facilitating reimbursement. Medicaid and private insurers also cover it, subject to formulary considerations.
Pricing Analysis
Current Pricing
- List Price: The wholesale acquisition cost (WAC) for Vaxneuvance is approximately $175 per dose.
- Average Selling Price (ASP): Typically 10-15% below WAC, roughly $150-$160 per dose.
- Reimbursement: Varies across payers, generally aligning with ASP.
Price Trends
Since launch, Vaxneuvance's price remains stable with slight adjustments related to inflation and market dynamics. The pricing strategy aligns with Pfizer’s Prevnar 13, which retail prices range from $165-$200 per dose depending on the distributor.
Market Penetration and Revenue Projections
- Initial market share: Estimated at 5-8% among adult pneumococcal vaccines in the U.S.
- Projected revenue (2023-2025):
| Year |
Projected Units Sold |
Revenue (approx.) |
Notes |
| 2023 |
2-3 million doses |
$300-$480 million |
Based on initial uptake |
| 2024 |
4-6 million doses |
$600-$960 million |
Growth driven by expanded use |
| 2025 |
8-10 million doses |
$1.2-$1.6 billion |
Market expansion continues |
Growth assumptions depend on regulatory approval for pediatric use, increased public health campaigns, and broader payer coverage.
Price Projection Factors
- Competitive pressure: Prevnar 13’s price point remains a benchmark, potentially limiting significant price increases.
- Market share expansion: As awareness and indications grow, demand could push prices marginally upward.
- Reimbursement policies: Payers’ willingness to reimburse at current ASP levels sustains revenue. Price hikes are limited by market competition and policy constraints.
Risk Factors
- Patent status and biosimilar entry could influence pricing pressures.
- Shift toward combination vaccines or alternative delivery platforms.
- Regulatory delays for pediatric or new indications.
Conclusion
The market for NDC 70515-0737 (Vaxneuvance) is poised for steady growth, supported by increasing demand for pneumococcal vaccines. Pricing remains stable with limited upward movement due to existing competitive benchmarks and reimbursement landscape. Revenue projections suggest significant growth in unit sales driven by broader indications and market penetration.
Key Takeaways
- Vaxneuvance's wholesale price approximates $175 per dose with ASP around $150–$160.
- Market growth is driven by increased indications, awareness, and payer coverage.
- Revenue is projected to reach over $1 billion annually by 2025 with unit sales expanding significantly.
- Competitive pressure from Prevnar 13 constrains pricing flexibility.
- Regulatory developments in pediatric indications and reimbursement policies are pivotal for future growth.
FAQs
1. What is the main competitor to NDC 70515-0737?
Prevnar 13 (Pfizer) is the primary competitor, with similar indications and slightly older serotype coverage.
2. How does pricing of Vaxneuvance compare internationally?
International prices vary significantly based on healthcare systems; typically, prices are lower outside the U.S. due to negotiated discounts and formulary policies.
3. What are the key factors influencing future price trends?
Market share growth, regulatory approvals, payer contracts, and competition are primary factors.
4. Is there potential for biosimilar entry?
Yes, biosimilars or generic alternatives might emerge if patent protections expire or licensing agreements are established, impacting pricing.
5. How does vaccination coverage influence market size?
Higher coverage rates in high-risk populations increase demand, leading to increased sales and revenue.
References
- MarketWatch. (2022). Pneumococcal Vaccines Market Size, Share & Trends.
- CDC. (2022). Pneumococcal Disease and Vaccines.
- FDA. (2021). Approval of Vaxneuvance for Adults.
- IQVIA. (2022). Global Vaccines Market Report.
- MedPage Today. (2022). Pneumococcal Vaccination Trends and Policies.
